Triple therapy term is used in management of pulmonary artery hypertension, COPD and cystic fibrosis. Let us now read in next 2 minutes a quick recap of this must asked topic for your forthcoming competitive examinations. Triple Therapy for Pulmonary Arterial Hypertension (PAH) Endothelin Receptor Antagonists (ERAs) Example: Bosentan, Ambrisentan, Macitentan Action: Blocks endothelin, a vasoconstrictor, to reduce pulmonary vascular resistance. Phosphodiesterase-5 (PDE-5) Inhibitors or Soluble Guanylate Cyclase (sGC) Stimulators Example (PDE-5): Sildenafil, Tadalafil Example (sGC stimulator): Riociguat Action: Increases nitric oxide (NO) signaling to promote vasodilation. Prostacyclin Analogues or Prostacyclin Receptor Agonists Example: Epoprostenol, Treprostinil, Selexipag Action: Mimics prostacyclin to dilate blood vessels and inhibit platelet aggregation. This combination targets multiple pathways involved in PAH pathophysiology, offering better control of the disease. Triple Therapy for COPD Triple therapy for Chronic Obstructive Pulmonary Disease (COPD) involves a combination of inhaled medications to manage symptoms and reduce exacerbations. Long-Acting Beta-2 Agonists (LABA) Example: Salmeterol, Formoterol, Indacaterol Action: Broncho dilates airways for symptom relief and improved airflow. Long-Acting Muscarinic Antagonists (LAMA) Example: Tiotropium, Glycopyrrolate, Umeclidinium Action: Reduces bronchoconstriction by blocking muscarinic receptors in the airways. Inhaled Corticosteroids (ICS) Example: Budesonide, Fluticasone, Beclomethasone Action: Reduces airway inflammation and frequency of exacerbations. Triple therapy (LABA + LAMA + ICS) is recommended for patients with moderate to severe COPD who have frequent exacerbations despite dual therapy. Triple Therapy for Cystic Fibrosis (CF) For patients with Cystic Fibrosis, triple therapy specifically refers to the combination of CFTR modulators targeting different aspects of the CFTR protein defect (commonly associated with the F508del mutation). Elexacaftor Action: Facilitates the movement of defective CFTR protein to the cell surface. Tezacaftor Action: Improves CFTR protein processing and stability. Ivacaftor Action: Potentiates the function of the CFTR protein at the cell surface, enhancing chloride ion transport. This combination therapy significantly improves lung function and quality of life in CF patients with the F508del mutation. For more insightful information keep this page bookmarked. You can also check out this link https://marwahmedicine.com/newsite/bartter-syndrome-vs-gitelman-syndrome-a-must-know-topic-for-neet-pg-ini-cet-aspirants/

When preparing for NEET PG and INI-CET, mastering renal tubular disorders is crucial. Among these, Bartter Syndrome and Gitelman Syndrome are frequently tested due to their importance in clinical practice. Understanding their pathophysiology, clinical presentation, and lab findings with precision is essential for scoring high in medical entrance exams. Pathophysiology in a Nutshell Bartter Syndrome mimics the effect of chronic loop diuretics (e.g., furosemide), leading to salt-wasting and hypokalemia. Gitelman Syndrome mimics thiazide diuretics, causing hypokalemia, hypomagnesemia, and hypocalciuria. Clinical Case Example Case 1 Case 2 A 3-month-old infant presents with failure to thrive, polyuria, and hypokalaemia. Urinary calcium is high. Think Bartter Syndrome 15-year-old presents with muscle cramps, fatigue. Labs show hypokalaemia, hypomagnesemia and low urinary calcium. Think Gitelman Syndrome.   These clinical and biochemical differences should be memorized thoroughly to answer exam questions accurately. Bookmark this page on marwahMedicine.com for your last-minute revision!